Definitive Feasibility Study Sample Clauses

Definitive Feasibility Study. The Company shall have received, and delivered to the Purchasers and publicly filed with the SEC on Form 8-K, the final Definitive Feasibility Study, which final Definitive Feasibility Study shows (a) that the Xxxxxxxx Project’s Capital Costs are not in excess of 10% of the Current Capital Estimate, (b) that over the life of the mine (measured on a reserves-only basis) the Xxxxxxxx Project’s Operating Costs are not higher than $115/tonne (provided that Operating Costs in excess of $115/tonne will be permissible to the extent the Company demonstrates, to the Majority Purchasersreasonable satisfaction, that (x) such excess Operating Costs are being incurred based on a tradeoff optimization study and (y) such tradeoffs that result in such excess Operating Costs are economically beneficial to the Company and add value to the Xxxxxxxx Project), (c) that ore grades and mineable reserve and resources estimates are consistent with what was provided for in the PEA and (d) forecasted production levels, ramp up rates, royalty rates and all other key commercial factors are consistent with what was provided for in the PEA (and in respect of royalty rates, including the royalties granted to the Karlsson Group Inc., Grandhaven Energy LLC and Buffalo Management LLC in the amounts as publicly disclosed prior to the date of the Original Agreement).
AutoNDA by SimpleDocs
Definitive Feasibility Study. The PFS was prepared based upon an initial period of mining kaolinized granite as DSO and toll wet-refining overseas to generate early cashflows and to then convert to onsite wet-processing in Year 2. This would produce concentrated kaolinitic product that is shipped in bulk as filter cake for final toll wet-refining overseas in order to produce a premium bright-white halloysite-kaolin product for high value ceramic applications. A pre-tax NPV of A$736M and IRR of 175% was estimated by the PFS from annual sales of 233ktpa of refined kaolin produced (refer ADN ASX announcement dated 1 June 2020 titled “Pre-Feasibility Study Further Improves Poochera Halloysite-Kaolin Project Economics”). In an attempt to de-risk the project the DFS will evaluate alternative scenarios of a start-up 500,000tpa plant or a two-staged 250,000tpa modular phased wet-processing plant to be constructed at site, in preference to an initial DSO phase moving to 500,000tpa from Year 2 as contemplated under the PFS. In addition, the product specifications under the DFS have been altered from those considered in the PFS to a product with approximately 70% passing 2 microns (PFS was 90%) to meet the requirements of high-end ceramic manufacturers. The processed kaolin product has the brand name ‘Great White CRM’. The expected benefit of the new DFS approach is that high value product will be manufactured at site from the commencement of operations, from either an immediate 500,000tpa or two-staged wet-processing plant, tasking Project management with direct control to meet product quality specifications. The option to undertake DSO in the first 2 years of operations as proposed by the PFS will be further analysed under the DFS to consider the technical capabilities of identified refineries and perform more cost benefit analysis to ensure this to be the best option for the Project. Either of the early start-up scenarios will require bringing forward capital expenditure for construction of the plant. Under the PFS processing plant, capital expenditure was initially deferred such that plant construction would be funded by DSO sale revenues generated in the first two years of operation. Funding options are being considered under the DFS and for the following Bankable Feasibility Study (BFS) with significant assistance being provided by highly experienced corporate advisors Origin Capital. Project debt funding will be sourced to the benefit of both parties to the joint venture, with similar term...
Definitive Feasibility Study. (a) Upon GBR acquiring the Stage 2 Interest, and until completion of a Definitive Feasibility Study (DFS), GBR shall:

Related to Definitive Feasibility Study

  • Feasibility Study 4.3.1 The Feasibility Study shall identify any potential adverse system impacts that would result from the interconnection of the Generating Facility.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Production definitively discontinued 10.1. If the holder of the approval completely ceases to manufacture a vehicle type approved in accordance with this Regulation, he shall so inform the authority which granted the approval. Upon receiving the relevant communication that authority shall inform thereof the other Parties to the 1958 Agreement applying this Regulation by means of a communication form conforming to the model in Annex 1 to this Regulation.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Development Phase contractual phase initiated with the approval of ANP for the Development Plan and which is extended during the Production Phase while investments in xxxxx, equipment, and facilities for the Production of Oil and Gas according to the Best Practices of the Oil Industry are required.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Positive Test Results In the event an employee tests positive for drug use, the employee will be provided, in writing, notice of their right to explain the test results. The employee may indicate any relevant circumstance, including over the counter or prescription medication taken within the last thirty (30) days, or any other information relevant to the reliability of, or explanation for, a positive test result.

  • Deliverables at Triggering Event Dates; Certificates The Company agrees that on or prior to the date of the first Issuance Notice and, during the term of this Agreement after the date of the first Issuance Notice, upon:

Time is Money Join Law Insider Premium to draft better contracts faster.